| 41.3 0.16 (0.39%) | 11-14 12:53 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 51.02 | 1-year : | 59.6 |
| Resists | First : | 43.68 | Second : | 51.02 |
| Pivot price | 40.39 |
|||
| Supports | First : | 38.07 | Second : | 34.61 |
| MAs | MA(5) : | 41.07 |
MA(20) : | 39.77 |
| MA(100) : | 27.24 |
MA(250) : | 21.26 |
|
| MACD | MACD : | 1.5  |
Signal : | 1.7 |
| %K %D | K(14,3) : | 64.8 |
D(3) : | 63.7 |
| RSI | RSI(14): 61.5 |
|||
| 52-week | High : | 43.68 | Low : | 9.56 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ARWR ] has closed below upper band by 28.6%. Bollinger Bands are 22% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 41.52 - 41.8 | 41.8 - 42.03 |
| Low: | 39.68 - 39.95 | 39.95 - 40.17 |
| Close: | 40.74 - 41.18 | 41.18 - 41.55 |
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
Wed, 12 Nov 2025
Arrowhead Pharma (ARWR) Analysts Maintain Rating as Price Target Rises | ARWR Stock News - GuruFocus
Fri, 07 Nov 2025
Arrowhead Pharmaceuticals (ARWR) Nears FDA Decision on Plozasiran Following Key Novartis Licensing Deal - Sahm
Thu, 06 Nov 2025
Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Year-End Results - Business Wire
Thu, 06 Nov 2025
Arrowhead Pharmaceuticals (ARWR): Exploring Valuation After a 7% Climb and Strong Year-to-Date Gains - Sahm
Tue, 04 Nov 2025
Arrowhead Pharmaceuticals to Participate in Upcoming November 2025 Conferences - Business Wire
Wed, 29 Oct 2025
Arrowhead Pharmaceuticals (ARWR): Exploring Valuation After Shares Surge Over 20% This Month - Sahm
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 138 (M) |
| Shares Float | 120 (M) |
| Held by Insiders | 4.4 (%) |
| Held by Institutions | 78 (%) |
| Shares Short | 11,650 (K) |
| Shares Short P.Month | 11,860 (K) |
| EPS | -1.21 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.77 |
| Profit Margin | -25.9 % |
| Operating Margin | -596.3 % |
| Return on Assets (ttm) | -6 % |
| Return on Equity (ttm) | -37.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 4.14 |
| Sales Per Share | 4.14 |
| EBITDA (p.s.) | -0.62 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 22 (M) |
| Levered Free Cash Flow | -48 (M) |
| PE Ratio | -34.55 |
| PEG Ratio | 0 |
| Price to Book value | 10.96 |
| Price to Sales | 10 |
| Price to Cash Flow | 262.4 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|